Altimmune, Inc. announced Impairment loss on intangible asset of $12.4 million was recognized during the three months ended December 31, 2023 related to the acquired In-Process Research and Development asset associated with HepTcell. The overall response in the Phase 2 trial was deemed to be insufficient to warrant further advancement. As a result, any further development related to HepTcell has been stopped.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.33 USD | -0.81% | -8.49% | -34.84% |
May. 23 | Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM | |
May. 09 | Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.84% | 520M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ALT Stock
- News Altimmune, Inc.
- Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023